Clinicians in the UK should have the option to prescribe cannabis-derived medicinal products where appropriate, drug experts have concluded, paving the way for laws prohibiting their use to be relaxed.
News
Allergan, Molecular Partners’ AMD drug non-inferior to Lucentis
Allergan, Molecular Partners’ abicipar has shown non-inferiority to Novartis’ Lucentis but with fewer injections in late-stage trials involving patients with neovascular age-related macular degeneration.
NICE backs radionuclide therapy for some neuroendocrine tumours
A price cut has secured NHS funding for Advanced Accelerator Applications’ Lutathera as a treatment for some neuroendocrine tumours (NETs).
Be recognised for the part you play in targets being met
Ongoing training and development is key to a happy, motivated sales force and now, the PharmaTimes Sales Awards has a category dedicated to the people who make it happen.
Industry shows support for new Medical & Scientific Excellence Awards
News of the inaugural Medical & Scientific Excellence Awards has got the industry talking, with a number of entries already received.
Want to make a difference? Enter the new Charity Challenge
PharmaTimes media is partnering with Bowel Cancer UK and Beating Bowel Cancer to launch a Charity Challenge Award as part of the Communications Team of the Year competition.
Fly your company’s flag – ENTER NOW
With just six weeks to go until the prestigious PharmaTimes Marketer of the Year closes for entry, marketers at all levels of their career are looking forward to taking part in the 25th anniversary celebrations.
Sub-cutaneous form of Entyvio hits PhIII safety, efficacy goals
Takeda says it has late-stage trial results showing the benefit of an investigational subcutaneous formulation of Entyvio to patients with ulcerative colitis.
Kisqali wins speedy US breast cancer nod
Novartis’ Kisqali has been approved for breast cancer in the US less than one month after being filed with the US Food and Drug Administration.
Four pharmas named for breaching ABPI Code of Practice
Martindale Pharma, Pierre Fabre, Janssen and Pharmasure have all been named in advertisements for breaching the Association of the British Pharmaceutical Industry’s Code of Practice.
Dementia accounts for 12.7 percent of deaths
New data has revealed that Alzheimer’s disease and other forms of dementia accounted for 12.7 percent of all deaths in England and Wales last year.
Novartis bags rights to Galapagos/MorphoSys atopic dermatitis drug
Novartis has signed an exclusive global license agreement with Galapagos and MorphoSys for MOR106, a novel antibody directed against IL-17C.
NICE calls for quicker treatment of kidney stone patients in pain
The National Institute for Health and Care Excellence has released new draft guidelines calling for faster treatment of patients with kidney stones experiencing severe pain.
Record numbers taking part in life sciences industry research
The number of people taking part in NHS clinical research studies sponsored by the life sciences industry has risen dramatically over the last year, show new figures by the National Institute for Health Research (NIHR).
US approves Janssen’s HIV pill Symtuza
Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults.
